Brokers Issue Forecasts for Vivani Medical Q1 Earnings

Vivani Medical, Inc. (NASDAQ:VANI - Free Report) - Equities researchers at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of Vivani Medical in a report released on Monday, May 19th. HC Wainwright analyst Y. Chen expects that the company will post earnings per share of ($0.09) for the quarter. HC Wainwright has a "Buy" rating and a $4.00 price target on the stock. The consensus estimate for Vivani Medical's current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Vivani Medical's Q2 2026 earnings at ($0.08) EPS, Q3 2026 earnings at ($0.08) EPS, Q4 2026 earnings at ($0.08) EPS and FY2026 earnings at ($0.33) EPS.

Vivani Medical (NASDAQ:VANI - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.01).

Vivani Medical Trading Up 1.8%

VANI traded up $0.02 during midday trading on Thursday, hitting $1.15. 37,819 shares of the company were exchanged, compared to its average volume of 162,100. The company's 50 day simple moving average is $1.05 and its 200 day simple moving average is $1.16. The firm has a market capitalization of $68.13 million, a price-to-earnings ratio of -2.56 and a beta of 2.81. Vivani Medical has a 1-year low of $0.91 and a 1-year high of $2.09.

Insiders Place Their Bets

In related news, Director Gregg Williams purchased 44,400 shares of the business's stock in a transaction on Monday, April 7th. The shares were bought at an average cost of $0.99 per share, with a total value of $43,956.00. Following the transaction, the director now owns 4,799,200 shares of the company's stock, valued at approximately $4,751,208. This trade represents a 0.93% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last three months, insiders have purchased 121,662 shares of company stock valued at $121,636. Company insiders own 46.40% of the company's stock.

Institutional Investors Weigh In On Vivani Medical

Several hedge funds and other institutional investors have recently added to or reduced their stakes in VANI. Wealthedge Investment Advisors LLC acquired a new stake in shares of Vivani Medical during the 4th quarter valued at about $43,000. Jane Street Group LLC acquired a new stake in shares of Vivani Medical during the 4th quarter valued at about $66,000. Northern Trust Corp grew its position in shares of Vivani Medical by 19.1% during the 4th quarter. Northern Trust Corp now owns 71,915 shares of the company's stock valued at $83,000 after acquiring an additional 11,540 shares during the period. Finally, Connective Capital Management LLC grew its position in shares of Vivani Medical by 796.2% during the 1st quarter. Connective Capital Management LLC now owns 162,098 shares of the company's stock valued at $170,000 after acquiring an additional 144,010 shares during the period. 6.78% of the stock is owned by institutional investors and hedge funds.

About Vivani Medical

Vivani Medical, Inc, a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals.